Eradication of Malignant Carcinoma in the Breast Tissue

Breast Cancer Clinical Trial

Official title:

The Eradication of Malignant Carcinoma in the Breast Tissue Using an ATP (Adenosine-5'-Triphosphate) Inhibitor

Clinical Trial Details — Status: Completed

Administrative data

• NCT number: NCT02286778
• Other study ID #: F-9892131B
• Status: Completed
• Phase: Phase 2/Phase 3
• First received: November 3, 2014
• Last updated: August 2, 2017
• Start date: February 2016
• Est. completion date: August 1, 2017

Study information

• Verified date: August 2017
• Source: Optimal Health Research
• Contact: n/a
• Is FDA regulated: No
• Study type: Interventional

Clinical Trial Summary

The purpose of this study is to confirm the findings of an early study and expand our knowledge of treating Malignant Carcinoma in the Breast Tissue Using an ATP (Adenosine-5'-Triphosphate) Inhibitor.

Recruitment information / eligibility

• Status: Completed
• Enrollment: 60
• Est. completion date: August 1, 2017
• Est. primary completion date: January 2017
• Accepts healthy volunteers: No
• Gender: Female
• Age group: 35 Years to 75 Years

Eligibility

Inclusion Criteria:

• Clinical diagnosis of breast cancer

• Referred to the study by their treating physician

Exclusion Criteria:

• Any type of treatment for breast cancer before starting the study

Related Conditions & MeSH terms

• Breast Cancer

Intervention

Dietary Supplement:
• Acetogenins
Acetogenins BID for 12 months
• Placebo

Locations

Country	Name	City	State
n/a

Sponsors (1)

Lead Sponsor	Collaborator
Optimal Health Research

Outcome

Type	Measure	Description	Time frame	Safety issue
Primary	Number of participants tumor free	assessed by MRI	12 months